Research in our Department focuses on a wide variety of aspect of children's health. We study the neuroscience of pain in infants, HIV, immunology, haematology, gastroenterology, neuromuscular diseases and vaccinology.
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
10 December 2020
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
9 December 2020
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
23 November 2020
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
Expanding the Nude SCID/CID Phenotype Associated with FOXN1 Homozygous, Compound Heterozygous, or Heterozygous Mutations.
Giardino G. et al, (2021), J Clin Immunol
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
Davis K. et al, (2021), Lancet Infect Dis
Publisher Correction: A guide to vaccinology: from basic principles to new developments.
Pollard AJ. and Bijker EM., (2021), Nat Rev Immunol
Use of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) in X-Linked Myotubular Myopathy: Content Validity and Psychometric Performance.
Duong T. et al, (2021), J Neuromuscul Dis, 8, 63 - 77
SIMON: Open-Source Knowledge Discovery Platform
Tomic A. et al, (2021), Patterns, 2, 100178 - 100178
Diagnosing X-linked Myotubular Myopathy - A German 20-year Follow Up Experience.
Gangfuss A. et al, (2021), J Neuromuscul Dis, 8, 79 - 90
H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
Godfrey L. et al, (2021), Leukemia, 35, 90 - 106
For access to staff pages and student pages, please remember to log into the site with your Oxford Single Sign on at the top right hand side of the page.
If you're not immune to measles you can catch it just by going into a room up to 2 hours after an infected person has left it!